Abstract:The chromatin-reader protein ENL regulates oncogenic programs in acute myeloid leukaemia by binding via its YEATS domain to acetylated histones on the promoters of actively transcribed genes and recruiting the transcriptional machinery. Cancer cells often exploit transcription machinery and chromatin regulatory pathways to activate oncogenic gene expression programs. Chromatin regulatory mechanisms such as the recognition of modified histones by 'reader' proteins are therefore being explored as potential therapeutic targets in cancer. Here, Xiaobing Shi and colleagues show that ENL is a chromatin reader protein that regulates oncogenic programs in acute myeloid leukaemia (AML). It binds via its YEATS domain to acetylated histones on the promoters of actively transcribed genes and links to the transcriptional machinery. Depletion of ENL leads to anti-leukaemic effects, indicating that disrupting the interaction between the ENL YEATS domain and acetylated histones could be a potential therapeutic approach for AML, either alone or in combination with BET inhibitors. A related paper in this week's issue of Nature from James Bradner and colleagues provides further insights into the role of ENL in leukaemia. Cancer cells are characterized by aberrant epigenetic landscapes and often exploit chromatin machinery to activate oncogenic gene expression programs1. Recognition of modified histones by ‘reader’ proteins constitutes a key mechanism underlying these processes; therefore, targeting such pathways holds clinical promise, as exemplified by the development of bromodomain and extra-terminal (BET) inhibitors2,3. We recently identified the YEATS domain as an acetyl-lysine-binding module4, but its functional importance in human cancer remains unknown. Here we show that the YEATS domain-containing protein ENL, but not its paralogue AF9, is required for disease maintenance in acute myeloid leukaemia. CRISPR–Cas9-mediated depletion of ENL led to anti-leukaemic effects, including increased terminal myeloid differentiation and suppression of leukaemia growth in vitro and in vivo. Biochemical and crystal structural studies and chromatin-immunoprecipitation followed by sequencing analyses revealed that ENL binds to acetylated histone H3, and co-localizes with H3K27ac and H3K9ac on the promoters of actively transcribed genes that are essential for leukaemia. Disrupting the interaction between the YEATS domain and histone acetylation via structure-based mutagenesis reduced the recruitment of RNA polymerase II to ENL-target genes, leading to the suppression of oncogenic gene expression programs. Notably, disrupting the functionality of ENL further sensitized leukaemia cells to BET inhibitors. Together, our data identify ENL as a histone acetylation reader that regulates oncogenic transcriptional programs in acute myeloid leukaemia, and suggest that displacement of ENL from chromatin may be a promising epigenetic therapy, alone or in combination with BET inhibitors, for aggressive leukaemia.

Supplementary Data from KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplemental Figures S1-S11 from PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease

Impaired Cell Fate Through Gain-of-function Mutations in a Chromatin Reader.

Supplementary Data from SET Domain–Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence

Supplementary Figure 9 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Targeting the epigenetic reader ENL inhibits super-enhancer-driven oncogenic transcription and synergizes with BET inhibition to suppress tumor progression

The Gene Expression Level of M6a Catalytic Enzymes is Increased in ETV6/RUNX1-positive Acute Lymphoblastic Leukemia.

ENL Links Histone Acetylation to Oncogenic Gene Expression in Acute Myeloid Leukaemia

Additional File 1 of Super-enhancer Profiling Identifies Novel Critical and Targetable Cancer Survival Gene LYL1 in Pediatric Acute Myeloid Leukemia

Retinoid-Sensitive Epigenetic Regulation of the Hoxb Cluster Maintains Normal Hematopoiesis and Inhibits Leukemogenesis.

Supplementary Data from Adhesion GPCR ADGRE2 Maintains Proteostasis to Promote Progression in Acute Myeloid Leukemia

Supplementary Figure 4 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers

Hotspot Mutations in the Structured ENL YEATS Domain Link Aberrant Transcriptional Condensates and Cancer.

Comprehensive analysis of m6A methylome and transcriptome by Nanopore sequencing in clear cell renal carcinoma

Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung